Nemus Bioscience (NMUS) 0.5600 $NMUS NEMUS Bios
Post# of 273242
Posted On: 09/17/2016 7:02:19 AM
Nemus Bioscience (NMUS) 0.5600 $NMUS
NEMUS Bioscience, Inc. to Attend Upcoming Investment Conferences
Marketwire Canada - Wed Sep 07, 7:01AM CDT
COSTA MESA, CA--(Marketwired - Sep 7, 2016) - NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing, and commercializing cannabinoid therapeutics, announces that it will present at two investor conferences in September, 2016. Dr. Brian Murphy, CEO, will present at The Rodman & Renshaw 18th Annual Global Investment Conference in New York City, and the Aegis Capital Growth Conference in Las Vegas, where the management team will also conduct one-on-one meetings with investors.
Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.
Marketwire Canada - Fri Jun 10, 7:59AM CDT
COSTA MESA, CA and TAMPA, FL--(Marketwired - Jun 10, 2016) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced it signed a letter of intent (LOI) with Teewinot Life Sciences Corp. that is expected to lead to signing of a license agreement in which NEMUS would license biosynthetically-derived cannabinoid molecules based on NEMUS' proprietary prodrug technology.
NEMUS Bioscience Identifies Unique Cannabidiol (CBD) Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program
Marketwired - Thu Jun 02, 7:30AM CDT
COSTA MESA, CA--(Marketwired - Jun 2, 2016) - NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced, in conjunction with the company's research and commercialization partner, the University of Mississippi (UM or the University), the identification of a unique cannabidiol (CBD) derivative possessing analgesic properties, that will be advanced through Investigational New Drug (IND)-enabling studies for the treatment of pain disorders, especially those related to neuropathy.
CANNAINVESTOR Magazine Top 20 Cannabis Stocks
ACCESSWIRE - Wed Apr 27, 8:00AM CDT
ATLANTA, GA / ACCESSWIRE / April 27, 2016 / CANNAINVESTOR Magazine, is pleased to announce its April/May issue Top 20 Cannabis Stocks and Cannabis Stocks to Watch. Our Top 20 Cannabis Stocks were chosen using 12 key metrics, which are not supplied to the general public. Employees of CANNAINVESTOR Magazine may own some stocks on our lists however employee stock ownership was not a factor in determining lists. Please visit www.cannainvestormag.com to sign up for a free subscription to our monthly CANNAINVESTOR Magazine.
NEMUS Bioscience CEO to Present at BIO CEO & Investor Conference
Marketwired - Tue Feb 02, 7:30AM CST
NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs, announces that Brian Murphy, MD, NEMUS Bioscience's CEO and CMO, will present at the BIO CEO & Investor Conference in New York City. The conference will be held February 8-9, 2016 at the Waldorf Astoria New York Hotel.
NEMUS Bioscience Provides Corporate Update on Prioritization of Developmental Pipeline
ACCESSWIRE - Tue Jan 05, 7:38AM CST
COSTA MESA, CA / ACCESSWIRE / January 5, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced that the company has completed a review of its product assets and will be implementing a corporate strategy based on the prioritization of drug candidates in the Company's pipeline according to a projected commercialization timeline. The asset review was prompted by the recent in-licensing of cannabidiol (CBD) derivatives from the company's research and commercial partner, the University of Mississippi ("UM"
. UM is the only entity in the United States with a forty-seven year history of isolating and studying cannabinoid molecules sanctioned with licensure by the Federal Government.
NEMUS Bioscience Prodrug of THC (NB1111) Completes Validation Stage of Glaucoma Testing and Development
ACCESSWIRE - Tue Jan 05, 7:30AM CST
COSTA MESA, CA / ACCESSWIRE / January 5, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced the completion of the validation stage of testing of its cannabinoid-based therapy being developed for the treatment and management of glaucoma. The therapy, NB1111, is a proprietary prodrug version of tetrahydrocannabinol (THC) that has been shown to reduce intraocular pressure (IOP) in a rabbit glaucoma model. This compound has been in-licensed from our commercial and research partner, the University of Mississippi.
Distinguished U.C.S.F. Professor, Donald I. Abrams, M.D., Joins NEMUS Bioscience Advisory Board
ACCESSWIRE - Mon Jan 04, 7:30AM CST
COSTA MESA, CA / ACCESSWIRE / January 4, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced that Donald I. Abrams, M.D., Professor of Clinical Medicine at the University of California, San Francisco (U.C.S.F.) and Chief of the Hematology-Oncology Division at San Francisco General Hospital, has joined the company's Scientific Advisory Board. Dr. Abrams, who earned his medical degree at the Stanford University School of Medicine, will provide consultative expertise in the areas of cancer research and the development of palliative care programs using cannabinoid-based medicines. In addition to his current research duties, Dr. Abrams also serves as an integrative oncologist at the U.C.S.F. Osher Center for Integrative Medicine and was co-editor of the Oxford University Press textbook of Integrative Oncology. Nationally, Dr. Abrams has served as President of the Society of Integrative Oncology and is a member of the National Cancer Institute's (NCI) Physician Data Query: Complementary and Alternative Medicine (NCI
DQ(R) CAM) editorial board.
Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Marketwired - Tue Dec 22, 7:30AM CST
NEMUS Bioscience, Inc. (OTCQB: NMUS) has entered into a research agreement with the Company's development and commercial partner, the University of Mississippi (UM), to advance specialized cannabinoid derivatives for the management of CIPN. The agreement was executed based on a series of studies using validated animal models of CIPN exposed to unique cannabinoid-based therapies conducted in the lab of Dr. Kenneth J. Sufka, professor of Psychology and Pharmacology and Research Professor with the National Center for Natural Products Research at UM.
Latest Studies and Clinical Trials Lead to Compelling Developments Indicating Cannabinoids May Contain Significant Analgesic Effects in Treating Various Diseases & Conditions
PR Newswire - Wed Dec 16, 9:00AM CST
Comprehensive studies and research efforts are lending support that medical marijuana & cannabinoids may be safe, demonstrate a modest analgesic effect and could provide a reasonable treatment option for treatment chronic non-cancer pain and other ailments & diseases. Today's leading companies with recent developments of interest are Cannabis Science, Inc. (OTC: CBIS), Compass Diversified Holdings (NYSE: CODI), NEMUS Bioscience, Inc. (OTC: NMUS), GW Pharmaceuticals (NASDAQ: GWPH) and Insys Therapeutics, Inc. (NASDAQ: INSY)
INSY: 13.84 (+0.38), CODI: 17.02 (+0.07), GWPH: 105.12 (+0.03)
NEMUS Announces In-Licensing of Cannabidiol (CBD) Derivatives From the University of Mississippi
Marketwired - Wed Dec 16, 7:30AM CST
NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced the in-licensing of derivative formulations of the cannabinoid molecule, cannabidiol (CBD). CBD is differentiated from tetrahydrocannabidiol (THC) in that it is a non-psychogenic cannabinoid with multiple associated activities in mammalian systems, including but not limited to, immune regulation, anti-inflammatory and anti-cancer activity, neuro-modulation and neuroprotective qualities. The in-licensing includes not only formulation derivatives of the CBD molecule but also multiple routes of administration and methods of use.
Nemus THC Pro-Drug Receives Patent in Japan
Marketwired - Thu Oct 22, 7:30AM CDT
Nemus Bioscience, Inc. (OTCQB: NMUS) has announced that the pro-drug of tetrahydrocannabinol (THC) in-licensed from the company's research and commercial partner, the University of Mississippi, has been granted a utility patent in Japan. The patent refers to the composition of matter and preparation of delta-9 THC amino acid esters and their methods of use. The lead Nemus compound in development for glaucoma, NB1111, would fall under this patent umbrella.
DigiPath Leverages Nevada Foothold to Expand in 2016
ACCESSWIRE - Wed Oct 21, 7:31AM CDT
SEATTLE, WA / ACCESSWIRE / October 21, 2015 / GreenWave Advisors Founder Matthew Karnes once called cannabis testing "the most attractive subsector of the industry," adding that it could generate close to a billion dollars in revenue by 2020. With a growing number of states legalizing recreational and/or medical marijuana, there's a growing need for a cohesive cannabis testing framework to avoid many of the problems created by inadequate initial laws passed in states like California and Colorado.
Nemus Bioscience Partners With Atheln to Accelerate Drug Development Pipelines
Marketwired - Mon Oct 05, 7:30AM CDT
Nemus Bioscience, Inc. (OTCQB: NMUS) has announced that it has signed a contract with Atheln, Inc., a California-based consulting group comprised of seasoned professionals skilled across the spectrum of drug development and product strategy, from chemistry/formulation to pre-clinical studies through NDA filing. Atheln will be focused on the development of the cannabinoid prodrug NB1111.
NEMUS Bioscience, Inc. to Attend Upcoming Investment Conferences
Marketwire Canada - Wed Sep 07, 7:01AM CDT
COSTA MESA, CA--(Marketwired - Sep 7, 2016) - NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing, and commercializing cannabinoid therapeutics, announces that it will present at two investor conferences in September, 2016. Dr. Brian Murphy, CEO, will present at The Rodman & Renshaw 18th Annual Global Investment Conference in New York City, and the Aegis Capital Growth Conference in Las Vegas, where the management team will also conduct one-on-one meetings with investors.
Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.
Marketwire Canada - Fri Jun 10, 7:59AM CDT
COSTA MESA, CA and TAMPA, FL--(Marketwired - Jun 10, 2016) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced it signed a letter of intent (LOI) with Teewinot Life Sciences Corp. that is expected to lead to signing of a license agreement in which NEMUS would license biosynthetically-derived cannabinoid molecules based on NEMUS' proprietary prodrug technology.
NEMUS Bioscience Identifies Unique Cannabidiol (CBD) Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program
Marketwired - Thu Jun 02, 7:30AM CDT
COSTA MESA, CA--(Marketwired - Jun 2, 2016) - NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced, in conjunction with the company's research and commercialization partner, the University of Mississippi (UM or the University), the identification of a unique cannabidiol (CBD) derivative possessing analgesic properties, that will be advanced through Investigational New Drug (IND)-enabling studies for the treatment of pain disorders, especially those related to neuropathy.
CANNAINVESTOR Magazine Top 20 Cannabis Stocks
ACCESSWIRE - Wed Apr 27, 8:00AM CDT
ATLANTA, GA / ACCESSWIRE / April 27, 2016 / CANNAINVESTOR Magazine, is pleased to announce its April/May issue Top 20 Cannabis Stocks and Cannabis Stocks to Watch. Our Top 20 Cannabis Stocks were chosen using 12 key metrics, which are not supplied to the general public. Employees of CANNAINVESTOR Magazine may own some stocks on our lists however employee stock ownership was not a factor in determining lists. Please visit www.cannainvestormag.com to sign up for a free subscription to our monthly CANNAINVESTOR Magazine.
NEMUS Bioscience CEO to Present at BIO CEO & Investor Conference
Marketwired - Tue Feb 02, 7:30AM CST
NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs, announces that Brian Murphy, MD, NEMUS Bioscience's CEO and CMO, will present at the BIO CEO & Investor Conference in New York City. The conference will be held February 8-9, 2016 at the Waldorf Astoria New York Hotel.
NEMUS Bioscience Provides Corporate Update on Prioritization of Developmental Pipeline
ACCESSWIRE - Tue Jan 05, 7:38AM CST
COSTA MESA, CA / ACCESSWIRE / January 5, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced that the company has completed a review of its product assets and will be implementing a corporate strategy based on the prioritization of drug candidates in the Company's pipeline according to a projected commercialization timeline. The asset review was prompted by the recent in-licensing of cannabidiol (CBD) derivatives from the company's research and commercial partner, the University of Mississippi ("UM"
. UM is the only entity in the United States with a forty-seven year history of isolating and studying cannabinoid molecules sanctioned with licensure by the Federal Government. NEMUS Bioscience Prodrug of THC (NB1111) Completes Validation Stage of Glaucoma Testing and Development
ACCESSWIRE - Tue Jan 05, 7:30AM CST
COSTA MESA, CA / ACCESSWIRE / January 5, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced the completion of the validation stage of testing of its cannabinoid-based therapy being developed for the treatment and management of glaucoma. The therapy, NB1111, is a proprietary prodrug version of tetrahydrocannabinol (THC) that has been shown to reduce intraocular pressure (IOP) in a rabbit glaucoma model. This compound has been in-licensed from our commercial and research partner, the University of Mississippi.
Distinguished U.C.S.F. Professor, Donald I. Abrams, M.D., Joins NEMUS Bioscience Advisory Board
ACCESSWIRE - Mon Jan 04, 7:30AM CST
COSTA MESA, CA / ACCESSWIRE / January 4, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced that Donald I. Abrams, M.D., Professor of Clinical Medicine at the University of California, San Francisco (U.C.S.F.) and Chief of the Hematology-Oncology Division at San Francisco General Hospital, has joined the company's Scientific Advisory Board. Dr. Abrams, who earned his medical degree at the Stanford University School of Medicine, will provide consultative expertise in the areas of cancer research and the development of palliative care programs using cannabinoid-based medicines. In addition to his current research duties, Dr. Abrams also serves as an integrative oncologist at the U.C.S.F. Osher Center for Integrative Medicine and was co-editor of the Oxford University Press textbook of Integrative Oncology. Nationally, Dr. Abrams has served as President of the Society of Integrative Oncology and is a member of the National Cancer Institute's (NCI) Physician Data Query: Complementary and Alternative Medicine (NCI
DQ(R) CAM) editorial board. Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Marketwired - Tue Dec 22, 7:30AM CST
NEMUS Bioscience, Inc. (OTCQB: NMUS) has entered into a research agreement with the Company's development and commercial partner, the University of Mississippi (UM), to advance specialized cannabinoid derivatives for the management of CIPN. The agreement was executed based on a series of studies using validated animal models of CIPN exposed to unique cannabinoid-based therapies conducted in the lab of Dr. Kenneth J. Sufka, professor of Psychology and Pharmacology and Research Professor with the National Center for Natural Products Research at UM.
Latest Studies and Clinical Trials Lead to Compelling Developments Indicating Cannabinoids May Contain Significant Analgesic Effects in Treating Various Diseases & Conditions
PR Newswire - Wed Dec 16, 9:00AM CST
Comprehensive studies and research efforts are lending support that medical marijuana & cannabinoids may be safe, demonstrate a modest analgesic effect and could provide a reasonable treatment option for treatment chronic non-cancer pain and other ailments & diseases. Today's leading companies with recent developments of interest are Cannabis Science, Inc. (OTC: CBIS), Compass Diversified Holdings (NYSE: CODI), NEMUS Bioscience, Inc. (OTC: NMUS), GW Pharmaceuticals (NASDAQ: GWPH) and Insys Therapeutics, Inc. (NASDAQ: INSY)
INSY: 13.84 (+0.38), CODI: 17.02 (+0.07), GWPH: 105.12 (+0.03)
NEMUS Announces In-Licensing of Cannabidiol (CBD) Derivatives From the University of Mississippi
Marketwired - Wed Dec 16, 7:30AM CST
NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced the in-licensing of derivative formulations of the cannabinoid molecule, cannabidiol (CBD). CBD is differentiated from tetrahydrocannabidiol (THC) in that it is a non-psychogenic cannabinoid with multiple associated activities in mammalian systems, including but not limited to, immune regulation, anti-inflammatory and anti-cancer activity, neuro-modulation and neuroprotective qualities. The in-licensing includes not only formulation derivatives of the CBD molecule but also multiple routes of administration and methods of use.
Nemus THC Pro-Drug Receives Patent in Japan
Marketwired - Thu Oct 22, 7:30AM CDT
Nemus Bioscience, Inc. (OTCQB: NMUS) has announced that the pro-drug of tetrahydrocannabinol (THC) in-licensed from the company's research and commercial partner, the University of Mississippi, has been granted a utility patent in Japan. The patent refers to the composition of matter and preparation of delta-9 THC amino acid esters and their methods of use. The lead Nemus compound in development for glaucoma, NB1111, would fall under this patent umbrella.
DigiPath Leverages Nevada Foothold to Expand in 2016
ACCESSWIRE - Wed Oct 21, 7:31AM CDT
SEATTLE, WA / ACCESSWIRE / October 21, 2015 / GreenWave Advisors Founder Matthew Karnes once called cannabis testing "the most attractive subsector of the industry," adding that it could generate close to a billion dollars in revenue by 2020. With a growing number of states legalizing recreational and/or medical marijuana, there's a growing need for a cohesive cannabis testing framework to avoid many of the problems created by inadequate initial laws passed in states like California and Colorado.
Nemus Bioscience Partners With Atheln to Accelerate Drug Development Pipelines
Marketwired - Mon Oct 05, 7:30AM CDT
Nemus Bioscience, Inc. (OTCQB: NMUS) has announced that it has signed a contract with Atheln, Inc., a California-based consulting group comprised of seasoned professionals skilled across the spectrum of drug development and product strategy, from chemistry/formulation to pre-clinical studies through NDA filing. Atheln will be focused on the development of the cannabinoid prodrug NB1111.
(0)
(0)Scroll down for more posts ▼